证券代码：300253 证券简称：卫宁健康 公告编号：2024-065 债券代码：123104 债券简称：卫宁转债 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、回购股份方案的主要内容 （1）回购股份资金总额：人民币 4,000 万元至 8,000 万元（均 含）。具体以回购期满时实际回购股份使用的资金总额为准。 （2）回购股份用途：本次回购的股份将依法全部予以注销并减 少注册资本。 （3）回购价格：不超过人民币 8 元/股（含），该回购价格上限 不超过董事会审议通过回购方案决议前 30 个交易日公司股票交易均 价的 150%。 （4）回购数量：按回购价格上限和回购金额上下限测算，预计 回购股份数量约为 500 万股至 1,000 万股，占公司目前已发行总股本 比例为 0.23%至 0.46%。具体以回购结束时实际回购的股份数量为准。 卫宁健康科技集团股份有限公司 （5）回购资金来源：公司自有资金。 （6）回购期限：自公司股东大会审议通过本次回购方案之日起 不超过 12 个月。 （7）回购方式：集中竞价交易方式。 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-063 卫宁健康科技集团股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年9月5 日在公司会议室以现场和通讯相结合的表决方式召开了第六 届董事会第六次会议。会议通知于 2024 年 9 月 2 日以专人送达或电 子邮件方式发出。会议应出席董事 7 人，实际出席董事 7 人。本次董 事会的召集和召开符合《中华人民共和国公司法》和《公司章程》的 规定。会议由董事长周炜主持，公司监事及高级管理人员列席了本次 会议。经全体董事表决，形成决议如下： 一、逐项审议通过了《关于回购公司股份方案的议案》。 1.01 回购股份的目的 基于对公司内在价值的认可和对未来发展前景的坚定信心，为维 护广大投资者利益，增加投资者信心，经综合考虑公司财务状况、经 营状况、未来盈利能力等因素，公司拟使用自有资金以集中竞价方式 回购公司部分股份，回购的股份将全部予以注销并相应减少注册资 本。 表决结果：7 名赞成；0 名弃权 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-064 卫宁健康科技集团股份有限公司 第六届监事会第六次会议决议公告 《关于回购公司股份方案的公告》同日披露于巨潮资讯网。 二、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于调整 2022 年股权激励计划公司层面业绩考核目标的议案》。 公司本次公司层面业绩考核目标设置的调整综合考虑了外部环 境和企业实际情况，不会对公司的财务状况、经营业绩产生实质性影 响。本次调整能够更有效地将公司利益、股东利益和员工利益结合在 一起，实现对公司核心团队的有效激励，推动公司稳定发展。本次在 公司原有的业绩考核指标下增设阶梯式业绩考核及行权比例指标，不 会导致提前解除限售或降低授予价格的情形，不存在损害公司及全体 股东利益、特别是中小股东权益的情况，符合《上市公司股权激励管 理办法》等相关法律法规的规定。因此，监事会同意公司调整 2022 年股权激励计划公司层面业绩考核指标。 《关于调整 2022 年股权激励计划公司层面业绩考核目标的公 告》、《2022 年股票期权激励计划（草案）（2024 年 9 月修订）》、《2022 年股票期权激励计划（草 ...

上海市广发律师事务所 关于卫宁健康科技集团股份有限公司 2022 年股权激励计划相关事项的法律意见 本所律师根据法律的要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，对公司本次 2022 年股权激励计划事项出具如下法律意见。 一、本次 2022 年股权激励计划相关事项的批准与授权 致：卫宁健康科技集团股份有限公司 本所律师查阅了公司关于本次 2022 年股权激励计划事项的相关会议资料。 根据本所律师的核查，上述事项已经获得如下批准与授权： 上海市广发律师事务所（以下简称"本所"）接受卫宁健康科技集团股份有 限公司（以下简称"公司"）的委托，作为其 2022 年股票期权激励计划（以下 简称"2022 年股权激励计划"）的专项法律顾问，就本次 2022 年股权激励计划 相关事项，根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）、中国证 券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司股权激励管理 办法》（以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则 （2024 年修订）》（以下简称"《上市规则》 ...

卫宁健康（300253）/计算机 证券研究报告/公司点评 2024 年 9 月 1 日 | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------|--------------------------------------|---------|-------|-------|---------------------------|-------| | [Table_Industry] [Table_Title] 评级：买入（维持） \n市场价格： 5.45 元/股 | [Table_Finance] 公司盈利预测及估值 | \n2022A | 2023A | 2024E | 2025E | 2026E | | 分析师：闻学臣 | 营业收入（百万元） | 3,093 | 3,163 | 3,669 | 4,310 | 4,940 | | | 增长率 yoy% | 12% | 2% | 16% | 17% | 15% | | ...

计算机 证 券 研 究 报 告 2024 年 09 月 04 日 卫宁健康 (300253) ——利润端改善，互联网健康业务重回增长赛道！ | --- | --- | |------------------------------------|-------------------------------| | 市场数据： | 2024 年 09 月 04 日 | | 收盘价（元） | 5.21 | | 一年内最高/最低（元） | 8.38/5.11 | | 市净率 | 2.0 | | 息率（分红/股价） | 0.38 | | 流通 A 股市值（百万元） | 9,698 | | 上证指数/深证成指 | 2,784.28/8,226.24 | | 注："息率"以最近一年已公布分红计算 | | | --- | --- | |-------------------------------|-------------------------------| | | | | 基础数据 : | 2024 年 06 月 30 日 | | | | | 每股净资产（元） | 2.62 | | 资产负债率 % | 32.01 | ...

Investment Rating - The investment rating for the company is "Accumulate (Maintain)" [4] Core Views - The company reported a significant improvement in profit, focusing on the development of medical information technology [6] - In the first half of 2024, the company achieved revenue of 1.224 billion yuan, a year-on-year increase of 2.68%, and a net profit attributable to shareholders of 30 million yuan, up 81.83% year-on-year [2][6] - The company's gross margin was 41.35%, an increase of 0.68 percentage points year-on-year [2][6] - The second quarter of 2024 saw a revenue of 729 million yuan, a decrease of 1.81% year-on-year, and a net profit of 13.5 million yuan, down 83.09% year-on-year [2][6] Financial Performance Summary - Revenue for the first half of 2024 was 1.224 billion yuan, with a gross margin of 41.35% [6] - The company’s revenue is expected to grow to 3.512 billion yuan in 2024, with a year-on-year growth rate of 11.02% [7] - The net profit attributable to shareholders is projected to reach 475 million yuan in 2024, with a growth rate of 32.77% [7] - The company’s earnings per share (EPS) are expected to be 0.22 yuan in 2024, with a three-year compound annual growth rate (CAGR) of 31.92% [6][7] Business Segmentation - The company’s revenue is divided into the medical health information industry and the internet health industry, with revenues of 1.046 billion yuan and 178 million yuan respectively [6] - The medical health information segment saw a year-on-year decline of 2.12%, while the internet health segment grew by 44.25% [6] - The software sales, hardware sales, technical services, and internet health revenues were 566 million yuan, 144 million yuan, 336 million yuan, and 178 million yuan respectively, with varying year-on-year changes [6] Future Outlook - The company is expected to benefit from the ongoing development of medical information technology, with projected revenues of 4.039 billion yuan in 2025 and 4.662 billion yuan in 2026 [7] - The company maintains a leading market share in the core hospital system sector, with the new generation WiNEX product accelerating its market penetration [6][7]

Financial Performance - The company achieved operating revenue of CNY 1,223,742,976.83, representing a year-on-year increase of 2.68%[10]. - Net profit attributable to shareholders reached CNY 30,168,354.32, a significant increase of 81.83% compared to the same period last year[10]. - The net profit after deducting non-recurring gains and losses was CNY 21,479,567.62, reflecting a growth of 147.62% year-on-year[10]. - The company's cash flow from operating activities improved to -CNY 84,799,799.19, a 70.30% reduction in losses compared to the previous year[10]. - The total assets at the end of the reporting period were CNY 8,486,919,144.51, a decrease of 0.73% from the end of the previous year[10]. - The company's total revenue for the first half of 2024 reached 277.46 million yuan, up 77.91% from 155.96 million yuan in the same period of 2023[24]. - The net loss for the company in the first half of 2024 was 75.62 million yuan, a reduction of 47.58% compared to a net loss of 144.24 million yuan in the first half of 2023[24]. - The company's R&D investment in the first half of 2024 was 301 million yuan, accounting for 24.59% of its revenue[24]. Business Strategy and Operations - The company is implementing a "1+X" strategy, focusing on digital health applications and services to enhance its market position[17][18]. - The company continues to optimize its organizational structure and improve project management efficiency to drive growth in new orders and revenue[20]. - The company has successfully integrated new and existing product development to enhance its competitive edge in the healthcare information sector[20]. - The company is actively pursuing a share swap merger with Beijing Universal Medical Rescue Co., which is currently in progress but carries risks due to macroeconomic factors[23]. - The company aims to enhance operational service capabilities in insurance and health rights card businesses following strategic adjustments in 2023[23]. - The company is focusing on expanding its digital health services and enhancing the depth and breadth of internet healthcare offerings[23]. - The company is adapting to market competition by adjusting its project investments in response to the increasing number of similar products in the market[57]. Market Position and Competition - The company maintained the number one market share in China's core hospital diagnosis and treatment systems at 13.4% for 2023, marking the fourth consecutive year in this position[25]. - The company has established hundreds of WiNEX clients nationwide, enhancing digital transformation in hospitals and supporting high-quality development[21]. - The healthcare information industry is experiencing intensified competition, necessitating proactive management and increased R&D investment to enhance core advantages[66]. - The company is focusing on enhancing its market share and competitiveness through digital upgrades and innovative business models[58]. Shareholder and Financial Policies - The company reported a plan not to distribute cash dividends or bonus shares for the current period[1]. - The company aims to enhance shareholder returns through a sustainable profit distribution policy[75]. - The company has established a stable profit distribution policy to share development results with investors[83]. - The company’s major shareholder and actual controller committed not to reduce their holdings for six months starting from September 15, 2023[84]. - The company has not reported any issues or problems in the use and disclosure of raised funds[56]. Legal and Compliance - The company has not faced any administrative penalties due to environmental issues during the reporting period[82]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[86]. - The company has not engaged in any major related party transactions during the reporting period, ensuring transparency in its operations[89]. - The company has not reported any violations regarding external guarantees during the reporting period, reflecting sound financial practices[85]. Research and Development - The company has filed 74 new patents and obtained 55 new software copyright certificates during the reporting period[24]. - The company has established a comprehensive talent acquisition and training system, enhancing its professional service capabilities across research, sales, and service teams[37]. - The company emphasizes the importance of continuous innovation in technology and product development to maintain market competitiveness[65]. Risk Management - The company emphasizes the importance of understanding the risks associated with technology and product development, talent loss, industry competition, and seasonal fluctuations in operational performance[1]. - The management highlights the need for investors to recognize the difference between plans, forecasts, and commitments[1]. - The company faces talent retention risks in the software industry, which relies heavily on skilled personnel for product development and innovation[68]. - Seasonal fluctuations in revenue and cash flow are significant, with only 20%-30% of annual collections occurring in the first half of the year, while over 50% occurs in the fourth quarter[70]. Financial Reporting and Accounting - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the CEO and accounting head[1]. - The company adheres to the accounting standards and ensures that its financial statements reflect a true and complete picture of its financial status[165]. - The company has made significant adjustments in accounting policies, impacting the total income reported[142]. - The company emphasizes the importance of accurate financial reporting and compliance with relevant accounting standards in its operations[175].

证券代码：300253 证券简称：卫宁健康 公告编号：2024-062 卫宁健康科技集团股份有限公司 关于修订《公司章程》等内控制度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日召开了第六届董事会第五次会议，审议通过了《关于变更 公司注册资本及修订公司章程的议案》《关于修订<股东大会议事规则> 的议案》《关于修订<董事会议事规则>的议案》《关于修订<董事、监 事和高级管理人员所持公司股份及其衍生品种的变动管理制度>的议 案》等议案。根据《中华人民共和国公司法（2023 年修订）》《上市 公司章程指引（2023 年修订）》《上市公司监管指引第 3 号——上市 公司现金分红（2023 年修订）》《上市公司董事、监事和高级管理人 员所持本公司股份及其变动管理规则（2024 年修订）》《深圳证券交 易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管 理人员减持股份》等法律法规的规定，为保持内控制度与法律法规的 一致性，结合公司实际情况，公司拟对《公司章程》《股东大 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-059 卫宁健康科技集团股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 《2024 年半年度报告》、《2024 年半年度报告摘要》同日披露于 巨潮资讯网，《2024 年半年度报告摘要》同时刊登于《中国证券报》、 《上海证券报》、《证券时报》。 二、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于 2024 年半年度募集资金存放与使用情况的专项报告的议案》。 经审核，监事会认为：报告期内公司募集资金的管理、使用及运 作程序符合《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规和公司《募集资金管理办法》 的规定，募集资金的使用未发现违反法律、法规及损害股东利益的行 为。 《2024 年半年度募集资金存放与使用情况的专项报告》同日披 露于巨潮资讯网。 特此公告。 卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日在公司会议室以现场方式召开第 ...